12:00 AM
 | 
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Levadex: Completed QT/QTc study enrollment

Map completed enrollment and treatment of 54 healthy volunteers in a double-blind, placebo-controlled, crossover QT interval trial, which is being conducted in support of an NDA submission for Levadex to treat acute migraine. In January, FDA said...

Read the full 165 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >